Spero Therapeutics, a US biopharmaceutical company founded to develop novel therapies for the treatment of bacterial infections, has hired Cristina Larkin as Chief Commercial Officer.
Larkin has more than 22 years of experience developing commercial strategies for biopharmaceutical companies from Phase 1 studies to product launch. Her expertise covers various infectious disease products.
Prior to joining Cambridge, Massachusetts-based Spero, Larkin was Assistant Vice President at Forest Laboratories. There, she led the commercial hospital antibiotic franchise team and was responsible for the US launch and execution strategy for several antibiotics.
Before joining Forest Laboratories, Larkin held a variety of commercial roles at Ortho-McNeil Pharmaceutical, a division of Johnson and Johnson, in sales, managed markets, reimbursement and marketing.
